Melanoma tumor growth is accelerated in a mouse model of sickle cell disease

被引：7
作者：
Wang J. [1 ]
Tran J. [2 ]
Wang H. [1 ]
Luo W. [1 ]
Guo C. [1 ]
Harro D. [3 ]
Campbell A.D. [2 ]
Eitzman D.T. [1 ]
机构：
[1] University of Michigan, Department of Internal Medicine, Cardiovascular Research Center, 7301A MSRB III, 1150 West Medical Center Drive, Ann Arbor, 48109-0644, MI
[2] University of Michigan, Department of Pediatrics, Ann Arbor, MI
[3] University of Michigan Hospital, Chemical Pathology, Ann Arbor, MI
来源：
Experimental Hematology & Oncology | / 4卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Angiogenesis; Heme oxygenase-1; Melanoma; Sickle cell disease;
D O I：
10.1186/s40164-015-0014-1
中图分类号：
学科分类号：
摘要：
Background: The effect of sickle cell disease (SCD) on tumor growth is unknown. Sickled red blood cells may form aggregates within the microvasculature of hypoxic tumors and reduce blood flow leading to impairment of tumor growth. However, there is a paucity of data related to tumor growth in SCD. Methods: To investigate the effect of SCD on tumor growth in a melanoma model, we generated SCD and control mice using bone marrow transplantation and inoculated the chest wall with B16-F10 melanoma cells. Tumor growth was monitored and angiogenesis was studied in vivo and in vitro. Results: From day 1 to 21, tumor growth rate was nearly identical between SCD and WT mice, however from day 22 to day 29 tumor growth was accelerated in SCD mice compared to WT mice. Disparity in tumor size was confirmed at autopsy with an approximate 2-fold increase in tumor weights from SCD mice. Tumors from SCD mice showed increased vascularity and elevated levels of heme oxygenase-1 (HO-1). HO-1 inhibition with zinc protoporphyrin (ZnPP) blocked the angiogenic and tumor growth response to SCD in vivo and the response to hemin in vitro. Conclusions: Growth of melanoma tumors is potentiated in a mouse model of SCD. Therapies targeting angiogenesis or HO-1 may be useful in SCD patients with malignant tumors. © 2015 Wang et al.
引用
收藏
相关论文
共 31 条
  • [11] Livak K.J., Schmittgen T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, 25, 4, pp. 402-408, (2001)
  • [12] Baker M., Robinson S.D., Lechertier T., Barber P.R., Tavora B., D'Amico G., Jones D.T., Vojnovic B., Hodivala-Dilke K., Use of the mouse aortic ring assay to study angiogenesis, Nat. Protoc., 7, 1, pp. 89-104, (2012)
  • [13] Wang J.Y., Lee Y.T., Chang P.F., Chau L.Y., Hemin promotes proliferation and differentiation of endothelial progenitor cells via activation of AKT and ERK, J. Cell. Physiol., 219, 3, pp. 617-625, (2009)
  • [14] Jison M.L., Munson P.J., Barb J.J., Suffredini A.F., Talwar S., Logun C., Raghavachari N., Beigel J.H., Shelhamer J.H., Danner R.L., Et al., Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease, Blood, 104, 1, pp. 270-280, (2004)
  • [15] Nath K.A., Grande J.P., Haggard J.J., Croatt A.J., Katusic Z.S., Solovey A., Hebbel R.P., Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease, Am. J. Pathol., 158, 3, pp. 893-903, (2001)
  • [16] Weis S.M., Cheresh D.A., Tumor angiogenesis: molecular pathways and therapeutic targets, Nat Med, 17, 11, pp. 1359-1370, (2011)
  • [17] Belcher J.D., Mahaseth H., Welch T.E., Otterbein L.E., Hebbel R.P., Vercellotti G.M., Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice, J. Clin. Invest., 116, 3, pp. 808-816, (2006)
  • [18] Schultz W.H., Ware R.E., Malignancy in patients with sickle cell disease, Am. J. Hematol., 74, 4, pp. 249-253, (2003)
  • [19] Ryan T.M., Ciavatta D.J., Townes T.M., Knockout-transgenic mouse model of sickle cell disease, Science, 278, 5339, pp. 873-876, (1997)
  • [20] Paszty C., Brion C.M., Manci E., Witkowska H.E., Stevens M.E., Mohandas N., Rubin E.M., Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease, Science, 278, 5339, pp. 876-878, (1997)
1234